Saturday, May 30, 2026 U.S. Edition · Independent
Markets
CMPS 13.00 ▲ 9.06%
ATAI 4.57 ▲ 3.63%
GHRS 23.78 ▲ 6.26%
AXSM 233.72 ▲ 0.38%
NBIX 158.06 ▲ 1.07%
ACAD 21.82 ▲ 0.88%
LLY 1095.92 ▼ 2.74%
JNJ 226.73 ▼ 1.76%
ABBV 216.57 ▼ 0.94%
CURLF 3.56 ▲ 12.66%
GTBIF 8.01 ▲ 5.67%
TCNNF 9.67 ▲ 14.62%
VRNO 1.19 ▲ 6.25%
TLRY 5.59 ▼ 1.06%
CGC 1.11 ▼ 0.89%
MSOS 5.04 ▼ 1.56%
MJ 27.18 ▼ 0.18%
TDOC 7.94 ▲ 5.73%
HIMS 26.16 ▲ 3.07%
TALK 5.20 ▲ 0.19%
LFMD 4.37 ▼ 4.79%
ACHC 23.26 ▼ 2.10%
UHS 149.49 ▼ 0.42%
CMPS 13.00 ▲ 9.06%
ATAI 4.57 ▲ 3.63%
GHRS 23.78 ▲ 6.26%
AXSM 233.72 ▲ 0.38%
NBIX 158.06 ▲ 1.07%
ACAD 21.82 ▲ 0.88%
LLY 1095.92 ▼ 2.74%
JNJ 226.73 ▼ 1.76%
ABBV 216.57 ▼ 0.94%
CURLF 3.56 ▲ 12.66%
GTBIF 8.01 ▲ 5.67%
TCNNF 9.67 ▲ 14.62%
VRNO 1.19 ▲ 6.25%
TLRY 5.59 ▼ 1.06%
CGC 1.11 ▼ 0.89%
MSOS 5.04 ▼ 1.56%
MJ 27.18 ▼ 0.18%
TDOC 7.94 ▲ 5.73%
HIMS 26.16 ▲ 3.07%
TALK 5.20 ▲ 0.19%
LFMD 4.37 ▼ 4.79%
ACHC 23.26 ▼ 2.10%
UHS 149.49 ▼ 0.42%

Opinion

Editor's perspective on the mental health industry — labeled and separate from news reporting.

Read the executive order as a process change, not a methodological one

The voucher list does the talking. The same FDA that issued the Lykos CRL still issued the vouchers, and it sent them to programs whose methods it considers defensible. Sponsors who hear political acceleration as scientific accommodation will misread it as the field misread the original draft guidance, and pay the same kind of price.